Ligand Reports Second Quarter 2021 Financial Results
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Ligand to Report Second Quarter Financial Results on July 29, 2021
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
Ligand Reports First Quarter 2021 Financial Results
Ligand to Report First Quarter Financial Results on May 3, 2021
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
Ligand Receives Milestone Payment from Merck
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
